IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) - Total Liabilities
Based on the latest financial reports, IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) has total liabilities worth €2.60 Billion EUR (≈ $3.04 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) asset resilience to evaluate the company's liquid asset resilience ratio.
IPSEN SA SP.ADR 1/4/ EO 1 - Total Liabilities Trend (2021–2025)
This chart illustrates how IPSEN SA SP.ADR 1/4/ EO 1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see I7G0 total asset value.
IPSEN SA SP.ADR 1/4/ EO 1 Competitors by Total Liabilities
The table below lists competitors of IPSEN SA SP.ADR 1/4/ EO 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Avery Dennison Corp
NYSE:AVY
|
USA | $6.89 Billion |
|
SPIC Dongfang New Energy Corp
SHE:000958
|
China | CN¥85.34 Billion |
|
LG Chemicals
KO:051910
|
Korea | ₩52.25 Trillion |
|
Azrieli Group Ltd
TA:AZRG
|
Israel | ILA38.26 Billion |
|
Mapfre
MC:MAP
|
Spain | €48.00 Billion |
|
ICON PLC
NASDAQ:ICLR
|
USA | $7.02 Billion |
|
Britannia Industries Limited
NSE:BRITANNIA
|
India | Rs45.96 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down IPSEN SA SP.ADR 1/4/ EO 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See IPSEN SA SP.ADR 1/4/ EO 1 balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IPSEN SA SP.ADR 1/4/ EO 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IPSEN SA SP.ADR 1/4/ EO 1 (2021–2025)
The table below shows the annual total liabilities of IPSEN SA SP.ADR 1/4/ EO 1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.60 Billion ≈ $3.04 Billion |
+15.23% |
| 2024-12-31 | €2.26 Billion ≈ $2.64 Billion |
-9.68% |
| 2023-12-31 | €2.50 Billion ≈ $2.92 Billion |
+10.03% |
| 2022-12-31 | €2.27 Billion ≈ $2.66 Billion |
+0.82% |
| 2021-12-31 | €2.25 Billion ≈ $2.63 Billion |
-- |
About IPSEN SA SP.ADR 1/4/ EO 1
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more